|1.||Umezawa, Kazuo: 34 articles (01/2014 - 01/2003)|
|2.||Ozaki, Michitaka: 5 articles (01/2013 - 09/2008)|
|3.||Todo, Satoru: 5 articles (01/2013 - 09/2008)|
|4.||Miyajima, Akira: 4 articles (11/2013 - 04/2003)|
|5.||Kikuchi, Eiji: 4 articles (11/2013 - 01/2003)|
|6.||Horie, Ryouichi: 4 articles (01/2013 - 08/2005)|
|7.||Umezawa, K: 4 articles (01/2013 - 07/2005)|
|8.||Watanabe, Toshiki: 4 articles (04/2009 - 08/2005)|
|9.||Oya, Mototsugu: 3 articles (11/2013 - 01/2003)|
|10.||Horiguchi, Yutaka: 3 articles (04/2010 - 01/2003)|
01/01/2007 - "Our previous study demonstrated that a small cell-permeable NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses expression of proinflammatory cytokines and ameliorates mouse arthritis. "
01/01/2007 - "NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor."
|2.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
05/01/2011 - "Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo."
05/01/2011 - "Dehydroxymethylepoxyquinomicin suppressed the NF-κB activity of human gastric cancer cells NUGC-4 and 44As3Luc and blocked the adhesion of cancer cells to ECM when compared with the control. "
11/18/2007 - "Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines."
04/01/2009 - "Dehydroxymethylepoxyquinomicin (DHMEQ) is a new NF-kappaB inhibitor and is effective on various tumor cells with constitutively activated NF-kappaB. "
11/14/2008 - "A new NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) has a potential to be applied to clinical medicine as an anti-cancer and anti-inflammatory agent. "
|5.||Prostatic Neoplasms (Prostate Cancer)
05/01/2011 - "Recent studies report that NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibits proliferation and induces apoptosis in prostate cancer cell lines. "
01/01/2003 - "We have synthesized and explored the feasibility of using a novel nuclear factor (NF) kappaB inhibitor, a dehydroxymethylepoxyquinomicin designated as DHMEQ, against prostate cancer. "
08/01/2005 - "To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the inhibitory effect of a new nuclear factor kappaB (NF-kappaB) inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on IL-6 production and cachexia in an animal model of hormone-refractory prostate cancer. "
|1.||NF-kappa B (NF-kB)
|5.||Interleukin-6 (Interleukin 6)
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||Reactive Oxygen Species (Oxygen Radicals)
|10.||Macrophage Colony-Stimulating Factor
|1.||Transplantation (Transplant Recipients)